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Financial relationships exist among industry, scientiﬁc investigators, and academic medical centers. These
relationships can foster research in the basic sciences, clinical trials, health economics evaluations, and other
outcomes assessment studies. To govern the conduct of burden-of-illness and outcomes research studies
involving collaborations between industry and academia, we propose voluntary standards related to: 1) the
development of and adherence to standards for research conduct and reporting; 2) disclosure, discussion, and
management of potential impacts of ﬁnancial conﬂicts of interest; and 3) transparency in research methods and
open access to study results.
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Biomedical researchers in the United States and from
the international community are focusing increasingly on
relationships between industry and academia, and their
effects on the conduct and results of research studies (Als-
Nielsen et al, 2003; Baird, 2003; Danforth et al, 2001). Much
of the debate has centered around financial relationships
and disclosure between individual researchers and industry
sponsors, and the effect of conflicts of interest on biases
in conducting research and reporting results (Drazen and
Curfman, 2002). In 2001, the International Committee of
Medical Journal Editors modified their requirements for
submitted manuscripts specifically to address how conflicts
of interest may erode the trust in research publications
(Davidoff et al, 2001).
Studies report not only widespread financial relationships
but also associations between industry sponsorship and
pro-industry conclusions (Bekelman et al, 2003; Lexchin
et al, 2003). Some studies suggest that about one in four
academic investigators in biomedical research receives
funding from industry (Bekelman et al, 2003). Other studies
report that two-thirds of academic institutions maintain
financial relationships with venture entities that sponsor
faculty research (Pressman, 1999).
Concerns about research funding and collaborations can
extend beyond the realm of traditional clinical research,
namely studies that focus primarily on safety and efficacy
endpoints. They can also be applied to evaluations of
outcomes research studies and studies examining the
burden of illness.
Although we recognize perceived and real conflicts
involved with industry–academia partnerships in clinical
and outcomes research studies, and the need to minimize
biases in such research endeavors, we believe that study
results should be evaluated based on the quality of the
research, the strength of the analyses, and the reproduci-
bility of the results. Therefore, we propose standards in the
development and reporting of outcomes and burden-
of-illness studies in dermatology related to: (1) conducting
outcomes studies; (2) managing financial conflicts of
interest; and (3) promoting research transparency for
organizations and individuals.
How Much Focus Should There Be on
Financial Conﬂict of Interest?
Collaborations among industry, government, and academia
are widespread, and represent relationships that are en-
couraged by government to foster research, development,
and innovation (Bayh-Dole Act, 1980). These relationships
can accelerate the development of new technologies to
clinical practice, leading to significant health improvements.
At the same time, they raise ethical concerns regarding
research motives and conduct (Martin and Reynolds, 2002).
Johns et al (2003) have hypothesized that economic
partnerships between industry and academia erode the
public trust in academic institutions and the entire research
enterprise.
‘‘Positive’’ publication bias, that is, the publication of
study results demonstrating improvements in outcomes of
newer, experimental therapies relative to control groups, is
not a phenomenon limited to industry-sponsored research
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(Kjaergard and Als-Nielsen, 2002). It has been widely
reported that studies with positive results are more likely
to be published in biomedical journals than are studies
with negative results (Callaham et al, 1998). In an evaluation
of emergency medicine studies presented as abstracts,
and subsequently published as manuscripts, Callaham and
colleagues found bias evident when studies were submit-
ted for consideration. This was amplified further in the
selection of abstracts for both presentation and publication,
neither of which was strongly related to study design or
quality (Callaham et al, 1998). Therefore, researchers,
authors, reviewers, and editors all play a role in publica-
tion bias.
We believe that the debate surrounding industry–acade-
mia relationships has centered too much around financial
conflicts of interest and not enough on rigorous scrutiny of
the research itself. Bekelman et al (2003) reported that the
quality of industry-supported studies they examined was
relatively strong because authors explicitly defined study
outcome a priori, despite the fact that industry-sponsored
research tends to yield pro-industry conclusions. Another
evaluation of studies funded by industry also concluded
that study quality was equivalent to non-industry-supported
research (Lexchin et al, 2003).
We would argue that the quality of the study design and
execution should be just as, if not more, important than
financial conflicts to the critical evaluation of outcomes and
burden-of-illness studies. To borrow from the immortal
words of Martin Luther King, Jr, studies should ‘‘not be
judged by the color of their skin but by the content of their
character.’’
Industry Has a Vested Interest
There is no need to hide the fact that industry’s involve-
ment in basic, clinical, and outcomes research can be
motivated by self-interest. The same could be said to be
true of research sponsored by the government and
academia.
When faced with these challenges, industry is being
asked to take the lead in documenting the burden of
disease across patient populations, patient quality of life
over time, and the economic impact of changes in patient
management. In many cases, industry’s involvement in
outcomes research fills voids in our knowledge about the
impact of various diagnostic and therapeutic interventions
on the healthcare system, which are not addressed through
research focused on safety and efficacy as mandated by
regulatory agencies (Sullivan, 2002).
We should not deny industry the right to address these
critical questions, nor deny the opportunity for industry and
academia to collaborate to find the appropriate answers.
Instead of trying to stem the proliferation of such research
activities, we believe it is more prudent to address issues
openly, and establish parameters to ensure that such
collaborations yield scientifically rigorous and intellectually
honest results. As stated by Blank (1992) in this same
journal, fiscal and ethical ‘‘issues are manageable and need
not reduce the benefits to both industry and academia that
are inherent in this relationship.’’
Standards for Industry–Academia
Collaborations of Burden-of-Illness and
Outcomes Research Studies in Dermatology
We propose the following voluntary standards to govern
the conduct of burden-of-illness and outcomes research
studies in dermatology involving collaborations between
industry and academia.
Focus on quality studies that adhere to uniform
standards Industry and academia jointly have a responsi-
bility to establish and adhere to standards in conducting
research and reporting results. For clinical research studies,
the Consolidated Standards of Reporting Trials (CONSORT)
statement conveys to the reader, in a transparent manner,
why the study was undertaken, and how it was conducted
and analyzed (Begg et al, 1996; Altman et al, 2001). In the
outcomes and burden-of-illness arena, various authors and
organizations have developed and proposed standards
governing cost-of-illness, pharmacoeconomic, and quality-
of-life studies (Gold et al, 1996; Smith, 1998; Bloom et al,
2001; Garrison, 2003). Additional work needs to be carried
out in emerging areas of outcomes research and burden-of-
illness to create standards that apply across research
settings and geographies. By developing and adhering to
standards, outcomes research studies can be methodolo-
gically rigorous and reported consistently.
Acknowledge and manage ﬁnancial conﬂict of inter-
est Recognizing the potential for conflict and bias is as
important as the reporting of these relationships. Industry-
sponsored collaborations are likely to be motivated by
specific research questions involving commercial interests.
These motivations should be disclosed and debated up
front. When submitting abstracts to scientific conferences,
presenting studies verbally at meetings, or preparing
manuscripts for publication, researchers and investigators
should provide relevant details of their financial relation-
ships with biomedical companies (Davidoff et al, 2001).
Disclosures can include but are not limited to: (1) consulting
fees; (2) service on advisory boards; (3) ownership of equity;
(4) patent royalties; (5) honorariums for lectures; (6) fees for
expert testimony; and (7) research grants.
Promote transparency in research and do not restrict
investigator behavior The research environment should
promote open collaboration and information sharing. There
should not be any prohibitions on information dissemina-
tion, or restrictions on the publication of research results
regardless of their findings. Industry must maintain trans-
parency and ensure access to data by researchers, in
addition to balancing privacy, competitive, and intellectual
property considerations.
Conclusion
The evaluation of the burden of illness in dermatology is at
an exciting point in time. The resources available to assess
the burden of illness are exceeded only by human curiosity
and demands for more information. By establishing and
adhering to rigorous standards, managing conflicts, and
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maintaining research integrity, those in industry and academia
will learn from each other and flourish in these pursuits.
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